A Phase 3 interventional study of tiotropium bromide in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Completed at 28 sites in 4 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.
This study's enrollment of 261 is above the median of 70 across 2,926 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male or female patients with a clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) based on American Thoracic Society (ATS) guidelines with:
Exclusion criteria:
Endurance time during a constant work rate exercise test to symptom limitation
Time frame: 2 hours and 15 minutes after trial medication administration on Day 42
Constant work rate exercise test to symptom limitation
Time frame: 8 hours post-dose after 6 weeks of treatment
Breathing discomfort during constant work rate exercise test as measured by the modified Borg Scale
Time frame: 6 weeks
Dynamic lung hyperinflation during exercise as determined by IRVdyn (IC minus VT) and EELVdyn (TLC)
Time frame: 6 weeks
Evaluation of VE and VEcap during exercise (selected centers)
Time frame: 6 weeks
Evaluation of static lung hyperinflation as measured by RV/TLC and by TGV(FRC)/TLC
Time frame: 6 weeks
Evaluation of TAC (TAV = TLC(BOX)-VA(IG))
Time frame: 6 weeks
Evaluation of slow vital capacity (SVC)
Time frame: 6 weeks
Evaluation of maximal expiratory flow rates and volumes FEV1, FVC, FEF25-75%, FEF50%, FEF75%, SVC
Time frame: 6 weeks
Evaluation of TGV, Raw, SGaw and RV
Time frame: 6 weeks
Evaluation of SaO2, VO2, VCO2, Ti, Te, VE, VT, breathing frequency (f) during constant work rate exercise test
Time frame: 6 weeks
Physician's Global Assessment
Time frame: 6 weeks
Assessement of Pulse/heart rate and blood pressure in conjunction with spirometry and exercise
Time frame: 6 weeks
Changes in Physical examination and ECG
Time frame: 6 weeks
Occurrence of Adverse Events
Time frame: 6 weeks
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive→
Boehringer Ingelheim